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Inherited mutations in BRCA1, and, mainly, BRCA2 genes are associated with
increased risk of male breast cancer (MBC). Mutations in PALB2 and CHEK2
genes may also increase MBC risk. Overall, these genes are functionally linked
to DNA repair pathways, highlighting the central role of genome maintenance in
MBC genetic predisposition. MUTYH is a DNA repair gene whose biallelic germline
variants cause MUTYH-associated polyposis (MAP) syndrome. Monoallelic MUTYH
variants have been reported in families with both colorectal and breast cancer and
there is some evidence on increased breast cancer risk in women with monoallelic
variants. In this study, we aimed to investigate whether MUTYH germline variants may
contribute to MBC susceptibility. To this aim, we screened the entire coding region of
MUTYH in 503 BRCA1/2 mutation negative MBC cases by multigene panel analysis.
Moreover, we genotyped selected variants, including p.Tyr179Cys, p.Gly396Asp,
p.Arg245His, p.Gly264Trpfs∗7, and p.Gln338His, in a total of 560 MBC cases and
1,540 male controls. Biallelic MUTYH pathogenic variants (p.Tyr179Cys/p.Arg241Trp)
were identified in one MBC patient with phenotypic manifestation of adenomatous
polyposis. Monoallelic pathogenic variants were identified in 14 (2.5%) MBC patients,
in particular, p.Tyr179Cys was detected in seven cases, p.Gly396Asp in five cases,
p.Arg245His and p.Gly264Trpfs∗7 in one case each. The majority of MBC cases
with MUTYH pathogenic variants had family history of cancer including breast,
colorectal, and gastric cancers. In the case-control study, an association between
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the variant p.Tyr179Cys and increased MBC risk emerged by multivariate analysis [odds
ratio (OR)= 4.54; 95% confidence interval (CI): 1.17–17.58; p= 0.028]. Overall, our study
suggests thatMUTYH pathogenic variants may have a role in MBC and, in particular, the
p.Tyr179Cys variant may be a low/moderate penetrance risk allele for MBC. Moreover,
our results suggest that MBC may be part of the tumor spectrum associated with MAP
syndrome, with implication in the clinical management of patients and their relatives.
Large-scale collaborative studies are needed to validate these findings.
Keywords: male breast cancer, genetic susceptibility, BRCA1/2, MUTYH, NGS, MUTYH-associated polyposis
(MAP) syndrome, breast cancer risk
INTRODUCTION
Male Breast Cancer (MBC) is a rare disease whose etiology
appears to be associated with genetic factors. Inherited mutations
in BRCA1 and, mainly, BRCA2, predispose to MBC and account
for up to 13% of all cases in the Italian population (1). Even
though there is evidence supporting an association between
increased MBC risk and pathogenic variants in PALB2 and
CHEK2 (2–4), these two genes are unlikely to account for
a substantial fraction of MBC cases. Thus, additional genes
that may contribute to MBC genetic susceptibility need to be
investigated.
BRCA1, BRCA2, PALB2, and CHEK2 belong to or are
functionally linked to the Homologous Recombination (HR)
mechanism, one of the most important DNA Double-Strand
Break (DSB) repair pathways, highlighting the central role of
genome maintenance in MBC predisposition (5). Overall, the
maintenance of genomic integrity is achieved by a coordinated
interplay of different mechanisms of DNA repair, including
Mismatch Repair (MMR), Nucleotide Excision Repair (NER) and
Base Excision Repair (BER), in addition to DSB repair (6, 7).
While dysregulation of DSB repair is known to play a relevant
role in breast cancer (BC) pathogenesis, the involvement of other
DNA repair pathways in BC is much less established.
MUTYH encodes a DNA glycosylase involved in BER,
preventing 8-oxo-G:A mispairs generated by oxidative damage
(8). Oxidative DNA damage, including 8-oxoG, may be due to
hormonal metabolism and may contribute to BC susceptibility
(9, 10). In this context, it is noteworthy that BRCA1 and BRCA2
are also involved in 8-oxoG repair (11), thus further supporting
a possible role of BER and, more specifically, MUTYH in BC
pathogenesis.
Biallelic (homozygous or compound heterozygous) MUTYH
variants occur in 0.01–0.04% of European descent populations
and cause MUTYH-associated polyposis syndrome (MAP),
which predisposes patients to develop colorectal polyps and
colorectal cancer (12–19). Monoallelic (heterozygous) MUTYH
Abbreviations:ACMG,American College ofMedical Genetics andGenomics; BC,
breast cancer; BER, base excision repair; DSB, double-strand break; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; HGVS, Human
Genome Variation Society; HR, homologous recombination; MAP, MUTYH-
associated polyposis; MBC, male breast cancer; MMR, mismatch repair; NER,
nucleotide excision repair; NGS, next generation sequencing; OC, ovarian cancer;
OR, Odds Ratio; PR, progesterone receptor; CI, confidence interval.
variants occur in 1–2% of European descent populations and
are associated with an increased risk of colorectal cancer (14,
16–21). Several studies on extracolonic cancers in carriers of
MUTYH variants have been performed (21–26). The association
of MUTYH variants with malignancies other than colon
cancer is less robust, especially when establishing cancer
risks in heterozygous MUTYH individuals. Increased risks of
bladder and ovarian cancers have been reported for biallelic
mutation carriers, while slightly increased risks of gastric,
hepatobiliary, endometrial, and breast cancer have been observed
in monoallelic mutation carriers (27).
Overall, the association between MUTYH mutations and BC
risk remains controversial, some studies have shown an increased
BC risk among MUTYH mutation carriers, while others have
not (22–26, 28–30). An increased risk of BC associated with
biallelic and monoallelic variants of MUTYH has been reported
in BRCA1/2 mutation negative individuals (21–23, 26). A
higher frequency of monoallelic MUTYH mutations in families
with both breast and colorectal cancer has been also reported
compared to general population (21). Recently, an increased
BC risk has been also reported for women with the common
p.Gln338His variant (31).
To date the possible association between MUTYH variants
and MBC risk has not been investigated. MBC is recognized
as being primarily a hormone-dependent malignancy and is
widely accepted as an estrogen-driven disease specifically related
to hyperestrogenism (32) thus, oxidative DNA damage, due
to hormonal metabolism, may particularly contribute to BC
susceptibility in men. In this context, impairment of MUTYH
activity due to inactivating/pathogenic variants may contribute
to increase MBC risk.
To assess if MUTYH germline variants may contribute to
MBC susceptibility, we screened a large series of BRCA1/2
mutation negative MBC patients by sequencing the entire
MUTYH coding region. Furthermore, to explore whether
MUTYH variants were significantly associated withMBC risk, we
performed a case-control study of selectedMUTYH variants.
PATIENTS AND METHODS
Study Population
A total of 560 BRCA1/2 mutation negative MBC cases and
1,540 male controls, enrolled in the frame of the ongoing
Italian Multicenter Study on MBC (33), were included in the
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present study. For each MBC case, information on the main
clinical-pathologic characteristics were collected as previously
described (33, 34). Controls were male individuals without
personal history of cancer, enrolled under research or clinical
protocols, or blood donors. All controls were recruited in the
same geographical area of cases. For each study participant,
samples of blood or DNA from peripheral blood leukocytes were
collected. DNA from blood samples was extracted and quantified
as previously described (35). The study was approved by Local
Ethical Committee (Sapienza University of Rome, Prot. 669/17)
and informed consent for using information and biological
samples was obtained from all participants to the study.
MUTYH Gene Sequencing
A total of 503 MBC cases underwent next generation sequencing
(NGS) of a custom panel of 50 cancer susceptibility genes
including MUTYH. Briefly, paired-end libraries were prepared
using the Nextera Rapid Capture Custom Enrichment kit
(Illumina, San Diego, California, USA), pooled and loaded into
a MiniSeq system (Illumina) for automated cluster generation,
sequencing, and data analysis, including variant calling. Variant
annotation and filtering was performed with Illumina Variant
Studio Software version 2.2 against the human reference
genome GRCh37. Variants were classified as pathogenic or
likely pathogenic (collectively termed, pathogenic) according
to the American College of Medical Genetics and Genomics
(ACMG) recommendations (36). Briefly, variants were classified
as pathogenic if they had a truncating, initiation codon or
splice donor/acceptor effect or if pathogenicity was demonstrated
by functional studies supportive of a damaging effect on the
gene or gene product. All pathogenic variants were confirmed
by double-stranded Sanger Sequencing (primer sequences
are available upon request). Variants were named according
to Human Genome Variation Society nomenclature (HGVS,
hpp://www.hgvs.org).
Genotyping Analysis
Genotyping analysis of five MUTYH variants, rs34612342
(c.536A>G; p.Tyr179Cys), rs36053993 (c.1187G>A;
p.Gly396Asp), rs140342925 (c.734G>A; p.Arg245His),
rs587780751 (c.933+3A>C; p.Gly264Trpfs∗7), and rs3219489
(c.1014G>C; p.Gln338His), identified by NGS and selected
because previously proposed to be associated with increased risk
of extracolonic cancer, including BC, was performed by allelic
discrimination real-time PCR, in an ABI 7500 fast real-time PCR
instrument (Life Technologies, Carlsbad, California, USA), using
commercially available TaqMan SNP genotyping assays (Life
Technologies) and according to the manufacturer’s instructions.
The specific assay IDs used are: C_32911941_10 (rs36512342),
C_27860250_10 (rs36053993), C_166223223_10 (rs140342925),
C_362043726_10 (rs587780751), and C_27504565_10
(rs3219489). In each experiment, positive (cases for which
genotype was confirmed by Sanger Sequencing) and negative
(water) controls were always included. A total of 560 MBC
cases, including the 503 cases analyzed by NGS, and 1,540 male
controls were genotyped.
Statistical Analysis
Chi-square test was performed in a case-case analysis in order to
evaluate potential associations between pathogenic variants and
specific clinical-pathologic characteristics.
The genotype frequency for each variant was evaluated in both
series of cases and controls. The association between each variant
and overall MBC risk was measured by the odds ratio (OR)
and its corresponding 95% confidence interval (CI) by univariate
logistic regression, and also by a multivariate analysis including
adjustment for age, center and type of enrolment. A p-value
<0.05 was considered statistically significant. All the analyses
were performed using STATA version 13.1 statistical program.
RESULTS
Clinical-Pathologic Characteristics of MBC
Cases
The study population consisted of 560 BRCA1/2 mutation
negative MBC cases, enrolled in the frame of the ongoing
Italian Multicenter Study on MBC. Overall, mean age at first
BC diagnosis was 61.8 years (range 22–91 years); 91 cases
(16.2%) reported first-degree family history of breast and/or
ovarian cancer (BC/OC), 247 cases (44.1%) had first-degree
family history of cancer and 101 cases (18%) had a personal
history of cancer in addition to BC,mostly colorectal and prostate
cancer. The majority of male breast tumors were invasive ductal
carcinomas (85.9%), estrogen receptor positive (ER+, 94.2%),
progesterone receptor positive (PR+ 88.4%), and HER2 negative
(79.2%).
MUTYH Gene Sequencing in MBC Cases
The entire coding region of MUTYH was screened in 503
BRCA1/2 mutation negative MBC cases, by a custom multigene
panel using NGS technologies. MUTYH variants detected are
shown in Table 1. p.Tyr179Cys and p.Gly396Asp variants were
the most frequently detected pathogenic variants and were
identified in 1.6 and 1.0% of the MBC cases, respectively. The
common variant p.Gln338His was identified in 41.7% of theMBC
cases (Table 1).
Overall, pathogenic variants were identified in 15 (3.0%)
MBC cases (Table 2), 14 cases were carriers of monoallelic
(heterozygous) pathogenic variants and one case was
carrier of the biallelic p.Tyr179Cys/p.Arg241Trp (compound
heterozygous) pathogenic variants. The majority of MBC cases
with MUTYH pathogenic variants had family history of cancer
including breast, colorectal, and gastric cancers (Table 2). In
particular, the biallelic MUTYH pathogenic variant carrier was
a man diagnosed with BC at 51 years of age who developed
colon cancer, with phenotypic manifestation of adenomatous
polyposis, at early age (41 years) and had a first-degree relative
affected bymelanoma at young age (26 years).With the exception
of this case, clinical features of the other MBC patients with
MUTYH pathogenic variants did not suggest a MAP phenotype.
Overall, comparison of the clinical-pathologic characteristics
between MUTYH pathogenic variant carriers and non-carriers
did not show any statistically significant differences (Table 3).
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TABLE 1 | MUTYH variants detected by NGS in 503 BRCA1/2 mutation negative MBC cases a.
bLocation Nucleotide change Protein change Variant type dbSNP ID Frequency N (%)
Exon 2 c.37 G>A p.Ala13Thr Missense rs375349172 1 (0.2%)
Exon 2 c.64G>A p.Val22Met Missense rs3219484 40 (8.0%)
Exon 7 c.536A>G p.Tyr179Cys Missense rs34612342 8 (1.6%)
Exon 9 c.694A>T p.Thr232Ser Missense rs587782351 1 (0.2%)
Exon 9 c.721C>T p.Arg241Trp Missense rs34126013 1 (0.2%)
Exon 9 c.734G>A p.Arg245His Missense rs140342925 1 (0.2%)
Exon 10 c.919C>T p.Arg307Trp Missense rs759822330 1 (0.2%)
IVS 10 c.933+3A>Cc p.Gly264Trpfs*7 Frameshift rs587780751 1 (0.2%)
Exon 12 c.1014G>C p.Gln338His Missense rs3219489 210 (41.7%)
Exon 12 c.1037C>G p.Ser346Trp Missense rs587778538 1 (0.2%)
Exon 13 c.1187G>A p.Gly396Asp Missense rs36053993 5 (1.0%)
Exon 13 c.1258C>A p.Leu420Met Missense rs144079536 4 (0.8%)
Exon 13 c.1276C>T p.Arg426Cys Missense rs150792276 2 (0.4%)
Exon 16 c.1544 C>T p.Ser515Phe Missense rs140118273 6 (1.2%)
aNGS, Next Generation sequencing; MBC, Male Breast Cancer.
bPathogenic variants are shown in bold text.
cThis variant affects a splicing site and causes the skipping of exon 10 that leads to a premature stop codon.
TABLE 2 | Personal and family history of cancer in MBC cases with germline MUTYH pathogenic variantsa.
ID Variantb Personal history of cancer (age) First-degree family history of cancer (age)
#40 c.1187G>A (p.Gly396Asp) Breast (55) Prostate (85)
#61 c.1187G>A (p.Gly396Asp) Breast (70) Colorectal (56)
#138 c.1187G>A (p.Gly396Asp) Breast (66) Breast (50)
#153 c.1187G>A (p.Gly396Asp) Breast (51) –
#321 c.1187G>A (p.Gly396Asp) Breast (75) –
#146 c.536A>G (p.Tyr179Cys) Breast (80) Breast (45); Gastric (54)
#236 c.536A>G (p.Tyr179Cys) Breast (45) Breast (58); Colorectal (58)
#317 c.536A>G (p.Tyr179Cys) Breast (67); Prostate (68) –
#341 c.536A>G (p.Tyr179Cys) Breast (72) Breast (70); Esophageus (76)
#352 c.536A>G (p.Tyr179Cys) Breast (63) –
#376 c.536A>G (p.Tyr179Cys) Breast (61) Gastric (43); Liver (67)
#478 c.536A>G (p.Tyr179Cys) Breast (82) Colon (50)
#257 c.933+3A>C p.Gly264Trpfs*7) Breast (72) 3 Breast (72,76, na)a
#358 c.734G>A (p.Arg245His) Breast (79) Breast (65); Gastric (69)
#227 c.536A>G (p.Tyr179Cys); c.721C>T (p.Arg241Trp) Breast (51); Colon (41) Melanoma (26)
aMBC, Male Breast Cancer; na, not available.
bVariants nomenclature in according to RefSeq NM_001128425.1, NP_001121897.1.
Genotyping Analysis of Selected MUTYH
Variants in MBC Cases and Controls
MUTYH pathogenic variants, including p.Tyr179Cys
(rs34612342), p.Gly396Asp (rs36053993), p.Arg245His
(rs140342925), p.Gly264Trpfs∗7 (rs587780751), and the
common variant p.Gln338His (rs3219489), were genotyped in
560 cases and 1,540 male controls. Overall, pathogenic variants
were detected at significantly higher frequency (p = 0.04) in
MBC cases (15/560 2.7%) than in controls (21/1540, 1.3%).
The distribution of genotype frequencies and the estimates
for the association between each genotyped variant and overall
MBC risk are summarized in Table 4. Significant differences
in the distribution of genotypes between MBC cases and
controls emerged for p.Tyr179Cys (rs34612342) variant. The
analysis of the genotype-specific risks showed that men
with heterozygous genotype for MUTYH p.Tyr179Cys variant
were at increased BC risk both in the univariate (OR =
5.56; 95%CI:1.67–18.55; p = 0.005) and in the multivariate
analysis (OR = 4.54; 95%CI:1.17–17.58; p = 0.028). No
statistically significant differences in genotype distribution
between case and controls emerged for the other variants
analyzed.
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TABLE 3 | Clinical-pathologic characteristics of MUTYH pathogenic variant carriers and non-carriers.
Characteristicsa MUTYH variant carriers (N = 15) Non-carriers (N = 488) p-value
N % N %
Mean age at diagnosis ± SD (range) 65.9 ± 11.4 (45–82) 61.7 ± 12 (22–91) 0.2
FIRST-DEGREE FAMILY HISTORY OF BC/OCb
Negative 13 86.6 411 84.4
Positive 2 13.4 76 15.6 1
FIRST-DEGREE FAMILY HISTORY OF CANCER
Negative 6 40.0 274 56.3
Positive 9 60.0 213 43.7 0. 3
PERSONAL HISTORY OF CANCER IN ADDITION TO BC
Negative 12 80.0 396 81.1
Positive 3 20.0 92 8.9 1
TUMOR HISTOTYPE
Invasive ductal carcinoma 13 92.9 342 83
In situ ductal carcinoma 1 7.1 36 8.7
Other – – 34 8.3 0.9
TNM STAGE
0 1 7.1 33 9.8
1 6 42.9 152 45.4
2 6 42.9 95 28.4
3–4 1 7.1 55 16.4 0.7
HISTOLOGIC GRADE
1 1 7.7 44 13.3
2 9 69.2 198 59.8
3 3 23.1 89 26.9 0.9
LYMPH NODE STATUS
Negative 8 61.5 213 63.2
Positive 5 38.5 124 36.8 1
ERb STATUS
Negative 1 8.3 23 6.1
Positive 11 91.7 353 93.9 0.5
PRb STATUS
Negative 1 9.1 43 11.5
Positive 10 90.9 331 88.5 1
HER2b STATUS
Negative 11 91.7 236 80.0
Positive 1 8.3 59 20.0 0.5
Ki67/MIB1 STATUS
Low 2 28.6 172 58.9
High 5 71.4 120 41.1 0.1
aSome data for each pathologic characteristic are not available.
bBC, breast cancer; OC, ovarian cancer; ER, Estrogen receptor; PR, Progesterone receptor; HER2, human epidermal growth factor receptor 2.
DISCUSSION
In this study, we aimed to evaluate the contribution of MUTYH
variants inMBC susceptibility. To this purpose, we obtainedNGS
data of the entire coding region ofMUTYH from a large series of
BRCA1/2mutation negativeMBC cases, from the ongoing Italian
Multicenter Study on MBC, and further genotyped selected
variants in a case-control study. To date, there is contrasting
evidence on the impact of MUTYH pathogenic variants on risk
of BC in women and, to the best of our knowledge, no study has
been performed in MBC.
By NGS, we identified 15 MBC patients (3.0%) with germline
MUTYH pathogenic variants, including one biallelic and 14
monoallelic variant carriers. The MBC patient with biallelic
MUTYH pathogenic variants was affected by colorectal cancer
at early age with phenotypic manifestation of adenomatous
polyposis. Thus, our results allowed a molecular diagnosis of
MAP. To the best of our knowledge, to date, only another
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TABLE 4 | Distribution of 560 BRCA1/2 negative MBC cases and 1,540 controls according to genotype frequencies and MBC risk estimates for selected MUTYH
variantsa.
Univariate analysis Multivariate analysisb
Variant Genotype Cases N (%) Controls N (%) OR (95% CI) p-valuec OR (95% CI) p-valuec
p.Tyr179Cys (rs34612342) AA 552 (98.57) 1536 (99.74)
AG 8 (1.43) 4 (0.26) 5.56 (1.67–18.55) 0.005 4.54 (1.17–17.58) 0.028
p.Arg245His (rs140342925) GG 559 (99.8) 1540 (100)
GA 1 (0.2) – – – – –
p.Gly264Trpfs*7 (rs587780751) AA 559 (99.8) 1539 (99.94)
AC 1 (0.2) 1 (0.06) 2.75 (0.17–44) 0.455 0.94(0.04–19.95) 0.97
p.Gln338His (rs3219489) GG 327 (58.4) 931(60)
GC 203 (36.2) 526 (34.2) 1 (0.89–1.34) 0.36 1.2 (0.95–1.5) 0.12
CC 30 (5.4) 83 (5.4) 2.1 (0.66–1.59) 0.89 1.2 (0.76–2) 0.37
p.Gly396Asp (rs36053993) GG 555 (99.1) 1524 (99)
GA 5 (0.9) 16 (1) 0.86 (0.31–2.35) 0.77 0.58 (0.16–2.14) 0.42
aMBC, Male breast Cancer; OR, Odds Ratio; 95% CI, 95% confidence interval.
bORs and 95% CI for specific genotypes were calculated using logistic regression models adjusted for age, center and type of enrolment.
cp-values <0.05 in bold text.
MBC case has been reported with MAP syndrome (23). Taking
into account the rarity of both MBC and MAP, the occurrence
of MBC in MAP patients may underline a possible common
genetic pathway and suggest that MBC could be considered a
MAP-related malignancy.
Overall, MUTYH monoallelic pathogenic variants, including
p.Tyr179Cys, p.Gly396Asp, p.Arg245His, and p.Gly264Trpfs∗7,
were found with a frequency of 2.8% in our MBC series.
p.Tyr179Cys and p.Gly396Asp were the most frequently variants
detected and were identified in 2.4% of the cases. Published data
showed that these two variants are the most frequent pathogenic
variants in populations of European origin and account for 50 to
90% of MUTYH pathogenic variants identified in MAP patients
(13, 14, 37, 38). The p.Arg245His variant was identified in a
MBC patient with family history of breast and gastric cancers.
This variant has been reported strongly associated with familial
colorectal cancer (23, 39), and has also been identified in patients
with suspected Lynch Syndrome and in a patient with gastric
cancer (23, 40). The p.Gly264Trpfs∗7 variant was identified in
a MBC patient, from North-East of Italy, where it occurs as a
founder mutation accounting for about 15.0% of the MUTYH
pathogenic variants identified in MAP patients (41). By contrast,
this variant has been reported with lower frequency, ranging
from 1.0 to 8.0%, in MAP patients from other populations of
Caucasian ethnicity (23, 41–47).
To investigate whether MBC arising in MUTYH pathogenic
variant carriers may be characterized by specific features, we
compared clinical-pathologic characteristics between carriers
and non-carriers. No statistically significant association emerged
for any of the clinical features tested. However, the great
majority of MBC patients withMUTYH pathogenic variants had
family history of cancer, including, breast, colorectal, and gastric
cancers. These findings, if confirmed by additional data, may be
useful in decisions concerning clinical management of patients
and their families.
To further investigate the role of MUTYH in MBC, we
evaluated the risk of MBC associated with selected MUTYH
variants previously proposed to be associated with increased
cancer risk, including BC risk (21, 27, 31), by performing a
case-control study. Among the pathogenic variants examined,
the p.Tyr179Cys variant was associated with an increased MBC
risk (OR = 4.54, 95%CI = 1.17–17.58). A higher frequency of
p.Tyr179Cys has been reported in families with both breast and
colorectal cancer compared to the general population (21), but
an association between p.Tyr179Cys variant and increased BC
risk has not been observed (25, 26, 28, 30). Our results, suggest
that p.Tyr179Cys variant may be a low/moderate penetrance
risk allele for BC in men. This variant, located at 8-oxo-G
binding site, causes major structural protein changes and a
reduction in functionality (48, 49). Thus, oxidative DNA damage
due to hormonal metabolism, like estrogen-induced 8-oxo-dG
generation, may particularly contribute to MBC susceptibility, as
BC in men is primarily a hormone-dependent tumor, specifically
related to hyperestrogenism. Furthermore, it can be hypothesized
that MBC, unencumbered by the many confounding factors that
exist in female BC (i.e., reproductive factors and high frequency)
might facilitate the identification of genetic factors andmolecular
mechanisms that may influence BC risk in general (50).
We also assessed whether the common p.Gln338His variant,
reported to increase BC risk in women (31), was associated
with MBC risk. We did not observe any significant differences
in p.Gln338His genotypes distribution between MBC cases and
controls inconsistent with a possible role of this variant in
MBC risk. The other common variant, p.Val22Met, has not been
reported to be associated with cancer risk (51–53) and was not
examined in this study.
Overall, we observed that the majority of MBC patients with
pathogenic MUTYH variants have first-degree family history of
cancers. This raises the question of whether MUTYH variants,
especially the Tyr179Cys variant, may be associated with MBC
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risk only, or with the risk of familial or multi-syndromic diseases,
including MBC. Further clinical/phenotype assessments and
detailed statistical analyses would be useful in future studies to
answer this question.
In conclusion, our study suggests that MUTYH pathogenic
variants may have a role in MBC, in particular, p.Tyr179Cys
variant may be a low/moderate penetrance risk allele for
MBC. Our findings also suggest that MBC may be part of
the tumor spectrum associated with MAP syndrome, with
implications in the clinical management of the patients and their
relatives.
Although we have a large series of MBC cases, this study
may be underpowered to detect smaller risk effects and large-
scale collaborative studies are needed to investigate any possible
association with rarer variants and to have amore comprehensive
examination and characterization of the link between MUTYH
variants and MBC risk.
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